Document Classification

Section Type: METHODS

Text: From February 1988 to May 1992, the ECOG entered previously untreated patients with active multiple myeloma on a study in which they were randomized to VBMCP (vincristine 1. 2 mg/m (2) administered intravenously [i. v.] on Day 1, BCNU 20 mg/m (2) i. v. on Day 1, melphalan 8 mg/m (2) administered orally [p. o.] on Days 1-4, cyclophosphamide 400 mg/m (2) i. v. on Day 1, and prednisone 40 mg/m (2) p. o. on Days 1-7 ; 5-week cycles) or VBMCP + rIFN (alpha2), the latter given at 5 Mu/m (2) 3 times a week starting on Day 22 of each 6-week cycle after 2 initial cycles of VBMCP.